From: gilmore o'neill/cambridge/biogen;nsf;gilmore.oneill@biogenidec.com;smtp
Sent: Wed Feb 01 2006 12:27:58 EST
To: dmiller@saturn.nmr.ion.ucl.ac.uk;
Subject: Fw: ENS abstract

Sorry, forgot to attach the minutes


Advisory Committee Minutes 040908_v2.doc

Gilmore N. O'Neill, M.B., M.R.C.P.I., M. Med. Sci.
Director
Clinical Development-Neurology
biogenidec
14, Cambridge Center, Bio 4
Cambridge, MA 02142
Tel: 617-679.2000
Fax: 617-679-3518
----- Forwarded by Gilmore O'Neill/Cambridge/Biogen on 02/01/2006 11:23 AM -----

Gilmore O'Neill/Cambridge/Biogen
02/01/2006 11:22 AM
Message Size: 2.8 KB

To
David Miller
cc

Subject
ENS abstract

Dear David,

as you are aware, we are putting together two abstracts for the ENS.

I pulled out the advisory commitee minutes from September 2004 to check on the authorship charter. I have attached the minutes below.

Would you be able to identify the following three people from the MRI reading centre who are supposed to be authors:

o Trial Manager
o Clinical Fellow (analyses scans)
o Consultant Neuroradiologist (supervises scan analysis)

Will they be able to sign authorship forms in time for the ENS deadline? We will probably send those out as soon as the SAC members have provided final comments on the abstracts.

Thanks and best regards

Gilmore

Gilmore N. O'Neill, M.B., M.R.C.P.I., M. Med. Sci.
Director
Clinical Development-Neurology
biogenidec
14, Cambridge Center, Bio 4
Cambridge, MA 02142
Tel: 617-679.2000
Fax: 617-679-3518

C-1900 Scientific Advisory Committee Meeting
Wednesday 8th September 2004

Attendees: Professor Kappos (LK), Professor Miller (DM), Professor Gold (RG), Dr Havrdova (EH), Professor Polman (CP), Dr Limmroth (VL), Dr Gilmore O'Neill (GO), Rebecca Conaghan (RC)

……..

Agenda:

- Discussion of authorship
- Data Safety Monitoring Committee
- New pre-clinical data
- Discussion to address any outstanding concerns about the C-1900 protocol, for example:
  - Patient Population
  - Endpoints (clinical and radiologic)
  - Treatment Groups
- AOB

General Issues

- Professor Kappos (LK) requested that the list of attendees for future meetings was added to the agenda when it is circulated
- LK suggested that it would be beneficial for the trial and the motivation of the investigators if the members of the Advisory Committee take more of an active role in the investigator meeting and be involved in some of the presentations, particularly on aspects of the protocol and study design. Everyone agreed that this would be a great motivating tool for all of the investigators
- Rebecca Conaghan (RC) will forward the protocol overview slides to LK to review and to determine if he would be interested in presenting some or all of them at the meeting.

Discussion Of Authorship

- The committee discussed who should be named as author on the study paper.
- There was general agreement that the entire Advisory Committee will be part of the writing group.
- Professor Miller (DM) requested that members of the team from the MRI Reading Centre are included on the paper due to the large role that they will play in processing the data from the study. There was general agreement on this.
- Dr O'Neill (GO) suggested that the top 3 highest enrollers are also included on the paper. If a member of the advisory committee is one of the highest enrollers then an additional investigator will not be added. Everyone was in agreement on this.
- The current list is to be forwarded to the Advisory Committee for their approval:

- Coordinating Investigator
- Advisory Committee Members
- 3 members of the MRI Reading Centre team
    - Trial Manager
    - Clinical Fellow (analyses scans)
    - Consultant Neuroradiologist (supervises scan analysis)
- Study Medical Director
- Lead Statistician
- Top 3 recruiting Investigators (not to be replaced if one of the top recruiting investigators is an advisory committee member)

Comment [GO1]: Should we do this?

Data Safety Monitoring Committee

- The entire Advisory Committee felt very strongly that an external Safety Monitoring Committee would be necessary. This will allow the members to be unblinded and therefore able to review all of the data and highlight any safety concerns.
- In addition it was pointed out that if there were to be any concerns in the future, Biogen Idec would not want to have only had an internal committee.
- It was agreed that the external committee should consist of at least 3 people. One of the members can be someone from the Advisory Committee as long as they are not an investigator in the study or involved in MRI review.
  (Post meeting note – further discussion has clarified that no members of the Advisory Committee should serve on the Independent Safety Committee even if they are not involved in recruiting patients).
  (Post meeting note – LK requested that if the DSMB wants to make specific proposals regarding the study this should be done through the Coordinating Investigator and the Medical director on behalf of the sponsor.)

New Preclinical Data

- GO reviewed the preclinical data from an ongoing toxicity study that was recently sent to all of the members.
- GO confirmed that the risk / benefit ratio to the patients remains unchanged.
- Following GO's explanation of the data, there were no further concerns.
- GO confirmed that the Investigators only need to inform their ethics committee.

Discussion to address any outstanding concerns about the C-1900 protocol, for example:

- **Patient Population**
- **Endpoints (clinical and radiologic)**
- **Treatment Groups**

- All of the members of the Advisory Committee were happy with the current version of the protocol with reference to patient population, endpoints (clinical and radiologic) and treatment groups. No additional concerns were raised.

AOB

- LK asked what will be in place for patients that have a positive response after 48 weeks on the study. It was pointed out that the first look at the data will be in November 2005 by which point, the first patients to be recruited into the study will have completed the trial. Ideally an extension protocol should be put into place.
- GO agreed to look into this and to report back to the committee.
- It was requested that a statement on this was available at the investigator meeting.

- Professor Gold (RG) updated the group regarding ongoing preclinical work with BG00012. .

- GO confirmed that if a patient is to be recruited on the inclusion criteria, *shows evidence of Gd-enhancing lesions of the brain on an MRI performed within 6 weeks prior to randomization,* this decision is to be made by the local investigator at that site.

- The next meeting will be scheduled for the start of November as recruitment will have been underway for a few weeks and so it will be a good opportunity to discuss recruitment and general progress to date.

C-1900 Advisory Committee Meeting Minutes – 8th September 2004

Signed: _____ Date: _____
Rebecca Conaghan
(Reviewed by Gilmore O'Neill)